BBIO
BridgeBio Pharma IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$14.01B
P/E Ratio
—
EPS
$-3.78
Beta
1.09
52W High
$84.94
52W Low
$28.32
50-Day MA
$71.38
200-Day MA
$61.55
Dividend Yield
—
Profit Margin
-144.40%
Forward P/E
—
PEG Ratio
—
About BridgeBio Pharma Inc
BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. The company is headquartered in Palo Alto, California.
Fundamentals
| Revenue (TTM) | $502.08M |
| Gross Profit (TTM) | $481.11M |
| EBITDA | $-496.63M |
| Operating Margin | -83.30% |
| Return on Equity | -1790.00% |
| Return on Assets | -33.80% |
| Revenue/Share (TTM) | $2.62 |
| Book Value | $-10.71 |
| Price-to-Book | 123.68 |
| Price-to-Sales (TTM) | 27.91 |
| EV/Revenue | 30.78 |
| EV/EBITDA | -9.40 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 2521.00% |
| Shares Outstanding | $193.86M |
| Float | $159.59M |
| % Insiders | 4.73% |
| % Institutions | 101.62% |
Analyst Ratings
Consensus ($100.64 target)
5
Strong Buy15
Buy1
HoldData last updated: 4/7/2026